Evidence map›Paper›PMID 42253510›Full record

ArticleHuman mutation2026

Integrative Multiomics Analysis Identifies a Novel Gene Signature That Predicts Chemotherapy Resistance and Poor Survival in Osteosarcoma.

Xiyu Yang, Xiaoming Lu, Zhiqiang Gao, Wentao Lv, Shenghuang Shen, Sijia Liu, Zetong Li, Ruixuan Liu, Xinyao Wang, Yao Shen and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human mutation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Xiyu YangDepartment of Pathology, Medical School of Nantong University, Nantong, China, ntu.edu.cn.
Xiaoming LuAffiliated Qidong Hospital of Nantong University, Qidong People's Hospital, Qidong Liver Cancer Institute, Qidong, China.
Zhiqiang GaoDepartment of Joint Surgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China, tongji.edu.cn.
Wentao LvDepartment of Medical Oncology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China, tongji.edu.cn.
Shenghuang ShenDepartment of Medical Oncology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China, tongji.edu.cn.
Sijia LiuDepartment of Medical Oncology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China, tongji.edu.cn.
Zetong LiDepartment of Pathology, Medical School of Nantong University, Nantong, China, ntu.edu.cn.
Ruixuan LiuDepartment of Pathology, Medical School of Nantong University, Nantong, China, ntu.edu.cn.
Xinyao WangDepartment of Pathology, Medical School of Nantong University, Nantong, China, ntu.edu.cn.
Yao ShenDepartment of Medical Oncology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China, tongji.edu.cn.
Danlei YuDepartment of Medical Oncology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China, tongji.edu.cn.
Xuanhong JinDepartment of Medical Oncology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China, tongji.edu.cn.ORCID https://orcid.org/0009-0002-9348-1837
Haowei WangDepartment of Medical Oncology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China, tongji.edu.cn.ORCID https://orcid.org/0009-0006-1361-197X
Jianfei TangDepartment of Orthopedic Surgery, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China, sjtu.edu.cn.ORCID https://orcid.org/0009-0006-1207-4586
Zhuoran TangDepartment of Pathology, Medical School of Nantong University, Nantong, China, ntu.edu.cn.ORCID https://orcid.org/0000-0002-9368-7192

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemotherapy resistance is the primary barrier to improving survival in osteosarcoma (OS), yet reliable predictive biomarkers remain limited. Here, we developed and validated a 13-gene signature via weighted gene coexpression network analysis (WGCNA) of chemotherapy-resistant and sensitive OS transcriptomes. The risk model demonstrated robust prognostic value across four independent cohorts (TARGET-OS, GSE21257, GSE16091, and GSE39055). Multiscale analysis revealed that high-risk tumors exhibit proliferative hyperactivation, genomic instability with elevated TMB, and a paradoxical immune-cold phenotype despite the high mutational load. Single-cell and spatial transcriptomics demonstrated that high-risk malignant cells display dedifferentiated, stem-like properties, preferentially localize to hypoxic necrotic peripheries, and engage in extensive tumor-stromal crosstalk. Drug sensitivity predictions confirmed resistance to first-line chemotherapy agents. Collectively, these findings establish a clinically actionable 13-gene biomarker and provide a mechanistic framework linking transcriptional profiles to chemoresistance biology, exposing novel therapeutic vulnerabilities in OS.

Indexed as

Biomarkers, TumorBone NeoplasmsDrug Resistance, NeoplasmOsteosarcomaTranscriptomeComputational BiologyGene Expression ProfilingGene Expression Regulation, NeoplasticGene Regulatory NetworksHumansMultiomicsPrognosisTumor MicroenvironmentBiomarkers, Tumorchemotherapy resistancegene signaturemultiomicsosteosarcomatumor microenvironment

Identifiers

PMID42253510
PMCPMC13239029

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.